← All trials
NCT05001282
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 13, 2021
- Primary completion
- Mar 15, 2024
- Completion date
- Mar 15, 2025
- First posted
- Aug 11, 2021
- Last posted
- Nov 19, 2021
- Enrollment
- 166
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Elucida OncologyLead sponsor
- Elucida OncologyStudy director
Drugs studied
Indications studied
- Carcinoma, Ovarian Epithelial
- Bile Duct Neoplasms
- Breast Neoplasms
- Colonic Neoplasms
- Esophageal Neoplasms
- Fallopian Tube Neoplasms
- Hamartoma
- Liver Neoplasms
- Neoplasm Metastasis
- Ovarian Diseases
- Ovarian Neoplasms
- Rectal Neoplasms
- Stomach Neoplasms
- Uterine Diseases
- Colorectal Neoplasms
- Endometrial Neoplasms
- Carcinoma, Endometrioid
- Cholangiocarcinoma
- Klatskin Tumor
- Triple Negative Breast Neoplasms
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.